Repurposing cardio-metabolic drugs to fight Covid19

Covid19 mostly manifests with interstitial pneumonia, even though it can afect heart and central nervous system as well. Although the pathophysiology of the clinical manifestations of Covid19 is not yet completely known, it has been shown that the entry of Sars-CoV-2 into cells is mediated by angiotensin-converting enzyme 2 (ACE2), expressed also in pulmonary epithelium [2]. After that, symptoms and the severity of Covid19 depend on the virus replication but also on the individual's immune response, often establishing an immune/infammatory storm leading to tissue damage that can have severe prognosis